Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 5.29 -2.58% -0.14
ATXI closed down 2.58 percent on Friday, October 18, 2019, on 1.68 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ATXI trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Slingshot Bearish Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Pocket Pivot Bullish Swing Setup -2.58%

Older signals for ATXI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.
Pharmaceutical Drugs Chemical Compounds Analgesics Pharmacokinetics Neurochemistry Hepatotoxins Amines Opioid Paracetamol
Is ATXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 7.98
52 Week Low 3.25
Average Volume 15,681
200-Day Moving Average 5.6171
50-Day Moving Average 5.9186
20-Day Moving Average 5.6288
10-Day Moving Average 5.4305
Average True Range 0.2529
ADX 41.96
+DI 11.3673
-DI 32.545
Chandelier Exit (Long, 3 ATRs ) 5.4913
Chandelier Exit (Short, 3 ATRs ) 5.7212
Upper Bollinger Band 6.0999
Lower Bollinger Band 5.1577
Percent B (%b) 0.14
BandWidth 16.738914
MACD Line -0.1858
MACD Signal Line -0.1577
MACD Histogram -0.0281
Fundamentals Value
Market Cap 53.12 Million
Num Shares 10 Million
EPS -0.44
Price-to-Earnings (P/E) Ratio -12.02
Price-to-Sales 0.00
Price-to-Book 1.57
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.88
Resistance 3 (R3) 5.94 5.81 5.78
Resistance 2 (R2) 5.81 5.66 5.78 5.74
Resistance 1 (R1) 5.55 5.57 5.49 5.49 5.71
Pivot Point 5.42 5.42 5.39 5.39 5.42
Support 1 (S1) 5.16 5.27 5.10 5.10 4.87
Support 2 (S2) 5.03 5.18 5.00 4.84
Support 3 (S3) 4.77 5.03 4.80
Support 4 (S4) 4.71